Acadia Pharmaceuticals (ACAD US): No Hallucination; Clear Path of Accelerated Growth Ahead
Acadia is well-positioned to report accelerated double-digit revenue growth through 2025 driven by new Rett syndrome drug launch in the US and...
511 Views
Neuren Pharmaceuticals (NEU AU): It’s Not Too Late to Join the Bandwagon; More Stream Is Still Left
Neuren’s North American partner gained FDA approval for its first drug, triggering milestone and royalty payment. Reasonable valuation and upcoming...
475 Views
SK Biopharm Valuation Analysis (What Is the Market Implying from SK Holdings?)
In this insight, we provide a valuation analysis of SK Biopharmaceuticals (BIO SK).Bullish Case Valuation - If we take a bullish case valuation...
537 Views
SK Biopharm IPO Preview
SK Biopharmaceuticals (BIO SK) is getting ready to complete an IPO in the Korean stock market in June. The SK Biopharm will be one of the biggest...
414 Views
Acadia Pharma: Hedge Fund Favorite and Upcoming Catalyst.
We took another look at P2 trial design for Acadia Pharmaceuticals Inc (ACAD US) Alzheimer's disease Psychosis ADP trial (results expected later...
706 Views